GASTRIC ADENOCARCINOMA

This is the first study in people for a new drug called KK2269. It aims to find a safe dose and see how well the body tolerates it. The study will test KK2269 alone in people with various advanced solid tumors, and also test it combined with a standard chemotherapy drug (docetaxe…

This is the first study in humans testing a new cancer drug called AVA6103. The trial aims to find a safe dose and see if the drug shows early signs of helping patients with advanced solid tumors that have spread or cannot be removed by surgery. It will enroll adults with specifi…

This study is observing how well a new targeted drug called zolbetuximab works when combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. It aims to confirm the drug's effectiveness and safety in real-world patie…

This early-stage trial is testing a new drug called BL-M05D1 in people with advanced cancers that have spread and stopped responding to standard treatments. The study will enroll 120 patients with specific cancers like stomach, pancreatic, and esophageal cancer to determine the s…

This early-stage study is testing whether an experimental drug called NRM-823 is safe and can help control advanced cancers that have stopped responding to standard treatments. Researchers will give NRM-823 alone and combined with immunotherapy to about 150 adults with various so…

This study is testing a two-part treatment for stomach cancer that has spread to the lining of the abdomen. First, patients receive chemotherapy and a minimally invasive heated chemo wash. Then, they undergo major surgery to remove visible tumors, followed by another heated chemo…

This study is testing whether a new drug called BL-M07D1 works better than standard chemotherapy for people with advanced HER2-positive stomach or gastroesophageal cancer. It's for patients whose cancer has continued to grow despite their first round of treatment. The main goals …

This study is testing if an immunotherapy drug called dostarlimab works better than standard chemotherapy as a first treatment for adults with certain rare, advanced cancers that have spread or cannot be surgically removed. About 120 participants will be randomly assigned to rece…

This study is for people with advanced cancer that started in the upper digestive tract (like the stomach, pancreas, or bile ducts) and has spread to only a few other places. After three months of chemotherapy, if a special blood test finds no cancer DNA, patients are randomly as…

This study is testing a new three-drug combination for people with advanced stomach or gastroesophageal cancer that has a specific marker called HER2-positive. The main goals are to find the safest and most effective dose of the new drug fruquintinib when added to two standard ca…

This study is testing whether surgery to remove the stomach, combined with chemotherapy delivered directly into the abdomen, can help people with advanced stomach cancer that has spread to the abdominal lining. The trial aims to see if this combined approach improves survival and…

This study is testing a two-part treatment for stomach cancer that has spread to the abdominal lining. Doctors use a robotic system to perform minimally invasive surgery to remove visible tumors, then bathe the area with heated chemotherapy. The goal is to see if this combined ap…

This study is testing whether adding an immunotherapy drug (sintilimab) to standard chemotherapy after surgery helps prevent stomach or esophageal junction cancer from coming back. It will involve about 70 adults with stage III cancer who have already had surgery to remove their …

This is the first-ever human study of an experimental pill called PLX-61639. It is being tested in adults with advanced cancers that have a specific genetic flaw (SMARCA4 mutation) and have stopped responding to standard treatments. The main goals are to find a safe dose and see …

This study is testing a treatment plan that combines an immunotherapy drug (adebrelimab) with several chemotherapy drugs for people with a type of stomach or gastroesophageal cancer that can be removed with surgery. The goal is to see if giving this combination before and after s…

This early-stage trial is testing whether combining a newer immunotherapy drug (tislelizumab) with standard chemotherapy (FLOT) is safe and tolerable when given before surgery for certain stomach and esophagus cancers. The goal is to see if giving more chemotherapy before surgery…

This early-stage study is testing a new drug called APL-5125 in adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose, check for side effects, and see if the drug can shrink tumors, especially in colorectal canc…

This early-stage study is testing a new drug, IDE892, both alone and in combination with another drug called IDE397. It is for adults with advanced solid tumors that have a specific genetic change called MTAP deletion and have stopped responding to standard treatments. The main g…

This study is testing if adding a chemotherapy drug (paclitaxel) directly into the abdominal cavity, along with standard IV chemotherapy, works better than standard IV chemotherapy alone for people with advanced stomach cancer that has spread to the lining of the abdomen. Partici…

This study is for people with esophageal or stomach cancer that has spread to only a few other places in the body. It compares two approaches: standard chemotherapy alone versus a more aggressive strategy that adds targeted radiation and possibly surgery to the chemotherapy. The …

This early-stage study is testing whether adding an immune-boosting drug directly into the abdomen, along with standard immunotherapy and chemotherapy, can better treat stomach cancer that has spread to the abdominal lining. The goal is to see if this combination can reduce the a…

This study is testing if adding the drug tadalafil (Cialis) to standard chemotherapy before stomach cancer surgery is safe and helpful. Researchers want to see if this combination changes the environment around the tumor to make treatment more effective. About 10 patients with op…

This study is testing whether adding an immunotherapy drug called sintilimab to standard chemotherapy (SOX) after surgery helps keep stomach cancer from coming back. It will involve 460 patients with a specific high-risk type of stomach cancer (PD-L1 positive, Stage N3). The main…

This study is testing whether a new targeted treatment called IMC002 works better than standard options for people with advanced stomach cancer that has a specific marker called CLDN18.2. It's for patients whose cancer has continued to grow despite trying at least two other treat…

This study is testing a new drug called ASP2138 for people with advanced stomach, gastroesophageal junction (GEJ), or pancreatic cancer. The drug works by guiding the body's own immune cells to attack cancer cells that have a specific marker called CLDN18.2. Researchers will test…

This study is testing whether adding two newer drugs (pembrolizumab and trastuzumab) to standard chemotherapy before surgery can better control HER2-positive stomach and esophageal cancers. The goal is to shrink tumors before surgery and prevent cancer from returning. About 49 pa…

This study is testing if patients recover just as well after keyhole stomach cancer surgery when doctors do not use a standard abdominal drain tube. It will compare two groups of patients following the same enhanced recovery plan, with the only difference being the use of the dra…

This study aims to see if a new stool test, which looks for specific markers related to a common stomach bacteria, and a simple risk questionnaire can help detect stomach cancer earlier. It will enroll up to 15,000 adults aged 40 and older. People who test positive on either meth…

This study is a national registry that aims to collect information on how patients with advanced stomach or esophageal cancer are actually treated in everyday practice in Germany. It will follow about 1,900 patients for up to two years to understand common treatment sequences and…

This study aims to understand why some stomach changes turn into cancer while others don't. Researchers will follow 3,200 people with various stomach conditions, healthy individuals, and cancer patients to compare their characteristics over time. The goal is to identify risk fact…

This is an open label, phase II, multi-site trial evaluating the efficacy and safety of the combination of 5-FU, oxaliplatin, nal-IRI, and immunotherapy (plus trastuzumab for HER2-positive tumors) as first-line therapy for participants with advanced Esophageal and Gastric Adenoca…